Prosmart

Prosmart is an AI-driven biotechnology company specializing in the de novo design and optimization of functional proteins. The company leverages its proprietary platform, which integrates deep learning, structural biology, and high-throughput experimental validation to engineer novel biologics with superior properties. Prosmart's capabilities include the development of optimized antibodies, cytokines, and industrial enzymes, addressing critical challenges in stability, binding affinity, and manufacturability. With a focus on oncology, immunology, and synthetic biology, the company aims to accelerate the transition from computational design to clinical application. Prosmart has attracted significant investment from prominent venture capital firms, including Sequoia China and Hillhouse Capital, to advance its pipeline and platform technologies.